Puma Biotechnology, Inc. Announces Retirement of Charles R. Eyler as Senior Vice President of Finance and Administrator and Treasurer
February 12, 2019 at 10:15 pm
Share
On February 6, 2019, in connection with Charles R. Eyler’s upcoming retirement on February 15, 2019 from Puma Biotechnology, Inc. as Senior Vice President of Finance and Administrator and Treasurer, the Compensation Committee of the Board of Directors of the Company approved entering into a Transition and General Release Agreement with Mr. Eyler whereby he will receive a cash payment of $425,189 in connection with his retirement.
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
PUMA BIOTECHNOLOGY, INC. 
